DALLAS, Oct. 29, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Metabasis Therapeutics (Nasdaq:MBRX). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Metabasis Therapeutics (Nasdaq:MBRX) should be of particular interest to comparable biotechnology/healthcare companies: Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA), Biogen Idec Inc. (Nasdaq:BIIB) and Genzyme Corp. (Nasdaq:GENZ).
The full report is available at: http://www.stockpreacher.com/n/MBRX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Metabasis Therapeutics Inc. (MBRX) is a biopharmaceutical company focused on the discovery development of drugs. The Company's product pipeline includes product candidates and advanced discovery programs for the treatment of metabolic diseases such as diabetes and hyperlipidemia, which it refer to as its core assets, as well as product candidates and advanced discovery programs for the treatment of liver diseases such as hepatitis and primary liver cancer, which it refer to as its non-core assets.
Message Board Search for MBRX: http://www.boardcentral.com/boards/MBRX
In the report, the analyst notes:
"MBRX recently announced it has entered into a definitive merger agreement under which Ligand will acquire all of the outstanding shares of MBRX. Under the transaction, MBRX stockholders will receive a cash payment at the closing of the transaction of approximately $3.2 million, less MBRX's estimated net liabilities at closing and an amount to be deposited in the stockholders' representative's fund (Metabasis currently estimates the closing payment to be approximately $1.8 million in cash).
"MBRX announced on September 18, 2009, that on September 15, 2009, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market, notifying the Company that based upon the closing bid price of its common stock for the last 30 consecutive business days, the Company did not maintain a minimum closing bid price of $1.00 per share or more that is required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a grace period of 180 calendar days, or until March 15, 2010, in which to regain compliance."
To read the entire report visit: http://www.stockpreacher.com/n/SAY
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.
CONTACT: StockPreacher.com Jeff Bishop (469)-252-3505 email@example.com